Seek Returns logo

AZN vs. CYTK: A Head-to-Head Stock Comparison

Updated

Here’s a clear look at AZN and CYTK, comparing key factors like performance, valuation metrics, dividends, and financial strength. It’s built for investors or anyone curious to see how these two stocks match up.

Company Overview

AZN dominates in value with a market cap of 432.07 billion USD, eclipsing CYTK’s 3.74 billion USD by roughly 115.55×.

CYTK carries a higher beta at 0.81, indicating it’s more sensitive to market moves, while AZN remains steadier at 0.18.

AZN trades as an ADR, giving U.S. investors a simple on-ramp to its foreign shares, while CYTK remains a standard domestic listing.

SymbolAZNCYTK
Company NameAstraZeneca PLCCytokinetics, Incorporated
CountryGBUS
SectorHealthcareHealthcare
IndustryDrug Manufacturers - GeneralBiotechnology
CEOMr. Pascal Claude Roland Soriot D.V.M., M.B.A.Mr. Robert I. Blum
Price69.68 USD31.31 USD
Market Cap432.07 billion USD3.74 billion USD
Beta0.180.81
ExchangeNASDAQNASDAQ
IPO DateMay 12, 1993April 30, 2004
ADRYesNo

Performance Comparison

This chart compares the performance of AZN and CYTK over the past year by tracking the growth of an initial $10,000 investment in each (starting one year ago).

Hover over the lines to see the investment’s value and total return (%) at specific dates.

Data is adjusted for dividends and splits.

Valuation Metrics Comparison

The section examines key financial ratios to assess the valuation of AZN and CYTK based on earnings, cash flow, sales, and book value. Pay attention to the following notable points where extreme values stand out.

  • CYTK shows a negative P/E of -6.03, highlighting a year of losses, whereas AZN at 27.80 trades on solid profitability.
  • CYTK carries a sub-zero price-to-book ratio of -13.93, indicating negative equity. In contrast, AZN (P/B 5.26) has positive book value.
  • CYTK reports a negative Price-to-Free Cash Flow ratio of -9.14, showing a cash flow shortfall that could threaten its operational sustainability, while AZN at 22.33 maintains positive cash flow.
SymbolAZNCYTK
Price-to-Earnings Ratio (P/E, TTM)27.80-6.03
Forward PEG Ratio (TTM)2.5010.57
Price-to-Sales Ratio (P/S, TTM)3.93194.57
Price-to-Book Ratio (P/B, TTM)5.26-13.93
Price-to-Free Cash Flow Ratio (P/FCF, TTM)22.33-9.14
EV-to-EBITDA (TTM)13.68-8.64
EV-to-Sales (TTM)4.41231.90
EV-to-Free Cash Flow (TTM)25.07-10.89

Dividend Comparison

AZN delivers a 1.39% dividend yield, blending income with growth, whereas CYTK appears to retain its profits, possibly to fund operations, R&D, or other growth initiatives.

SymbolAZNCYTK
Dividend Yield (TTM)1.39%0.00%

Financial Strength Metrics Comparison

This section dives into the financial resilience of AZN and CYTK, spotlighting key metrics like liquidity, leverage, and debt coverage. Check out the standout observations below where notable differences or extremes pop up.

  • AZN’s current ratio of 0.90 signals a possible liquidity squeeze, while CYTK at 5.99 comfortably covers its short-term obligations.
  • AZN’s quick ratio of 0.70 suggests it may struggle to cover immediate liabilities without selling inventory or raising cash, whereas CYTK at 5.99 maintains a comfortable buffer of liquid assets.
  • CYTK has negative equity (debt-to-equity ratio -2.97), suggesting asset shortfalls, whereas AZN at 0.77 preserves healthier equity coverage.
  • AZN meets its interest obligations (ratio 7.95). In stark contrast, CYTK’s negative ratio (-6.14) means its operating earnings (EBIT) don't cover basic operations, let alone interest, signaling serious financial trouble.
SymbolAZNCYTK
Current Ratio (TTM)0.905.99
Quick Ratio (TTM)0.705.99
Debt-to-Equity Ratio (TTM)0.77-2.97
Debt-to-Assets Ratio (TTM)0.300.63
Interest Coverage Ratio (TTM)7.95-6.14